DE60010126D1 - Verzweigte substituierte aminoderivate vom 3-amino-1-phenyl-1h[1,2,4]triazol, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen - Google Patents

Verzweigte substituierte aminoderivate vom 3-amino-1-phenyl-1h[1,2,4]triazol, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen

Info

Publication number
DE60010126D1
DE60010126D1 DE60010126T DE60010126T DE60010126D1 DE 60010126 D1 DE60010126 D1 DE 60010126D1 DE 60010126 T DE60010126 T DE 60010126T DE 60010126 T DE60010126 T DE 60010126T DE 60010126 D1 DE60010126 D1 DE 60010126D1
Authority
DE
Germany
Prior art keywords
amino
triazol
phenyl
preparation
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60010126T
Other languages
English (en)
Other versions
DE60010126T2 (de
Inventor
Michel Geslin
Danielle Gully
Jean-Pierre Maffrand
Pierre Roger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of DE60010126D1 publication Critical patent/DE60010126D1/de
Application granted granted Critical
Publication of DE60010126T2 publication Critical patent/DE60010126T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60010126T 1999-12-17 2000-12-14 Verzweigte substituierte aminoderivate vom 3-amino-1-phenyl-1h(1,2,4)triazol, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen Expired - Lifetime DE60010126T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9915935A FR2802530B1 (fr) 1999-12-17 1999-12-17 Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
FR9915935 1999-12-17
PCT/FR2000/003536 WO2001044207A2 (fr) 1999-12-17 2000-12-14 Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2 4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
DE60010126D1 true DE60010126D1 (de) 2004-05-27
DE60010126T2 DE60010126T2 (de) 2005-04-28

Family

ID=9553380

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60010126T Expired - Lifetime DE60010126T2 (de) 1999-12-17 2000-12-14 Verzweigte substituierte aminoderivate vom 3-amino-1-phenyl-1h(1,2,4)triazol, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen

Country Status (34)

Country Link
US (1) US6806282B2 (de)
EP (1) EP1242389B1 (de)
JP (1) JP4146641B2 (de)
KR (1) KR100705525B1 (de)
CN (1) CN1293061C (de)
AR (1) AR031837A1 (de)
AT (1) ATE264847T1 (de)
AU (1) AU780711B2 (de)
BR (1) BR0017023A (de)
CA (1) CA2398772C (de)
CO (1) CO5251379A1 (de)
CZ (1) CZ302460B6 (de)
DE (1) DE60010126T2 (de)
DK (1) DK1242389T3 (de)
EA (1) EA004957B1 (de)
EE (1) EE04778B1 (de)
ES (1) ES2219436T3 (de)
FR (1) FR2802530B1 (de)
HK (1) HK1055947A1 (de)
HU (1) HUP0204080A3 (de)
IL (2) IL150037A0 (de)
IS (1) IS2315B (de)
ME (1) MEP12108A (de)
MX (1) MXPA02006033A (de)
NO (1) NO20022828L (de)
PL (1) PL203819B1 (de)
PT (1) PT1242389E (de)
RS (1) RS50289B (de)
SK (1) SK285994B6 (de)
TR (2) TR200401775T4 (de)
TW (1) TWI289554B (de)
UA (1) UA73333C2 (de)
WO (1) WO2001044207A2 (de)
ZA (1) ZA200204422B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226920B2 (en) * 2003-08-06 2007-06-05 Vertex Pharmaceuticals Inc. Aminotriazole compounds useful as inhibitors of protein kinases
JO3019B1 (ar) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
RU2474579C2 (ru) 2007-10-18 2013-02-10 Янссен Фармацевтика Нв Тризамещенные 1,2,4-триазолы
AU2009226988B2 (en) 2008-03-19 2013-05-23 Janssen Pharmaceutica Nv Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators
JP5486591B2 (ja) 2008-05-09 2014-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アセチルコリン受容体モジュレーターとしての三置換ピラゾール
US20130225583A1 (en) * 2010-10-21 2013-08-29 Gerald W. Shipps, Jr. Substituted amino-triazolyl pde10 inhibitors
EP3096756B1 (de) 2014-01-21 2024-06-12 Neurocrine Biosciences, Inc. Crf1-rezeptor-antagonisten zur behandlung von congenitaler adrenaler hyperplasie
CN104059027B (zh) * 2014-07-01 2015-10-28 河北大学 一类含1,2,4-三唑的(e)-甲氧基亚氨基苯乙酸甲酯类化合物及其制备方法和用途
MX2022002881A (es) * 2019-09-25 2022-06-08 Oncoarendi Therapeutics Sa Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3869167D1 (de) * 1987-03-27 1992-04-23 Kumiai Chemical Industry Co Phenyltriazol-derivate und insectizid.
US5795905A (en) * 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
FR2763337B1 (fr) * 1997-05-13 1999-08-20 Sanofi Sa Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
IS2315B (is) 2007-11-15
CN1293061C (zh) 2007-01-03
TWI289554B (en) 2007-11-11
EP1242389B1 (de) 2004-04-21
BR0017023A (pt) 2002-12-03
NO20022828D0 (no) 2002-06-13
ES2219436T3 (es) 2004-12-01
US20030162771A1 (en) 2003-08-28
IS6402A (is) 2002-05-28
SK8502002A3 (en) 2003-02-04
AU780711B2 (en) 2005-04-14
CZ20022099A3 (cs) 2002-09-11
IL150037A (en) 2007-02-11
PL203819B1 (pl) 2009-11-30
JP2003516975A (ja) 2003-05-20
AR031837A1 (es) 2003-10-08
CN1434808A (zh) 2003-08-06
KR20020061002A (ko) 2002-07-19
DK1242389T3 (da) 2004-08-09
NO20022828L (no) 2002-08-19
WO2001044207B1 (fr) 2002-06-06
IL150037A0 (en) 2002-12-01
JP4146641B2 (ja) 2008-09-10
KR100705525B1 (ko) 2007-04-10
DE60010126T2 (de) 2005-04-28
SK285994B6 (sk) 2008-01-07
ATE264847T1 (de) 2004-05-15
HUP0204080A2 (hu) 2003-04-28
CZ302460B6 (cs) 2011-06-01
EA200200523A1 (ru) 2002-12-26
EE200200331A (et) 2003-06-16
CO5251379A1 (es) 2003-02-28
CA2398772A1 (fr) 2001-06-21
YU43902A (sh) 2005-03-15
WO2001044207A2 (fr) 2001-06-21
EA004957B1 (ru) 2004-10-28
FR2802530A1 (fr) 2001-06-22
FR2802530B1 (fr) 2002-02-22
EE04778B1 (et) 2007-02-15
EP1242389A2 (de) 2002-09-25
MXPA02006033A (es) 2003-01-28
US6806282B2 (en) 2004-10-19
RS50289B (sr) 2009-09-08
MEP12108A (en) 2010-06-10
WO2001044207A8 (fr) 2001-07-12
ZA200204422B (en) 2003-11-26
HUP0204080A3 (en) 2005-01-28
TR200401775T4 (tr) 2004-09-21
AU2525901A (en) 2001-06-25
WO2001044207A3 (fr) 2001-12-20
UA73333C2 (en) 2005-07-15
CA2398772C (fr) 2011-07-05
PT1242389E (pt) 2004-08-31
TR200201600T2 (tr) 2002-10-21
HK1055947A1 (en) 2004-01-30
PL355811A1 (en) 2004-05-17

Similar Documents

Publication Publication Date Title
DE69622992T2 (de) Substituierte heterocyclische verbindungen, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
HUP0203542A3 (en) 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
HUP9801045A3 (en) Sulfonyl-amino-carboxylic acid derivatives, use thereof, pharmaceutical compositions containing them and process for their preparation
ATA256092A (de) Aminosäurederivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE69131813D1 (de) Amido-3-Pyrazol-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
HUP9801044A3 (en) Sulfonylamino-carboxylic acid derivatives, process for their preparation, their use and pharmaceutical compositions containing them
IL115685A0 (en) Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
HUP0204515A3 (en) 4-aminopiperidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
IL115483A0 (en) Urea derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
ATE252562T1 (de) Pyrazolcarbonsäurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
IL113625A0 (en) Amino acid derivatives processes for their preparation and pharmaceutical compositions containing them and their use
ATE222250T1 (de) Phenoxypropanolamin-derivate, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutischen zusammensetzungen
HUP0001943A3 (en) Benzimidazole and benzotriazole derivatives, their use, process for their preparation and pharmaceutical compositions containing them
HUP0002404A3 (en) Amino acid derivatives, pharmaceutical compositions comprising thereof, process for preparation them and their use
IL114670A0 (en) Guanidine derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
HUP0202934A3 (en) Arylsulfonamido-substituted hydroxamic acid derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof
DE60036102D1 (de) Purinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE69934781D1 (de) Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen
HUP9901485A2 (en) Heterocyclylcarboxamide derivatives, pharmaceutical compositions containing the same, process for their preparation and their use
HUP0000960A3 (en) Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same
DE60010126D1 (de) Verzweigte substituierte aminoderivate vom 3-amino-1-phenyl-1h[1,2,4]triazol, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE60033519D1 (de) Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen
DE69517936T2 (de) Substituierte 4-Phenyl-Thiazole Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammenstellungen die sie enthalten
DE69520870T2 (de) Esculetin Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammenstellung

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR

8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1242389

Country of ref document: EP

Representative=s name: TER MEER STEINMEISTER & PARTNER GBR PATENTANWA, DE